“We are pleased with the results of the Phase 1 study which demonstrate a favorable safety profile for PRGN-3005 UltraCAR-T. Our UltraCAR-T therapies continue to be...
– PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to...
